Tetanus Toxoid
Pediatric Brain Tumor
Gary Archer Ph.D.vaccinePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Pediatric Brain Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hycamtin Jeffrey N. Bruce | Phase 2 | BB |
CARMUSTINE Washington University School of Medicine | Phase 2 | BB |
Gm-Csf Gary Archer Ph.D. | Phase 1 | CC |
Human Cmv Pp65-Lamp Mrna-Pulsed Autologous Dcs Gary Archer Ph.D. | Phase 1 | CC |
iopofosine (¹³¹I) Cellectar Biosciences, Inc. | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Tetanus Toxoid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →